The biomarker-based diagnosis of Alzheimer's disease. 2—lessons from oncology

Geneva Task Force for the Roadmap of Alzheimer's Biomarkers

Research output: Contribution to journalReview article

18 Citations (Scopus)

Abstract

Biomarkers for the diagnosis of Alzheimer's disease (AD) are not yet validated for use in clinical settings. We aim to provide a methodological framework for their systematic validation, by reference to that developed for oncology biomarkers. As for this discipline, the steps for the systematic validation of AD biomarkers need to target analytical validity, clinical validity, and clinical utility. However, the premises are different from oncology: the nature of disease (neurodegeneration vs. cancer), the purpose (improve diagnosis in clinically affected vs. screening preclinical individuals), and the target population (mild cognitive impairment patients referring to memory clinics vs. general population) lead to important differences, influencing both the design of validation studies and the use of selected biomarkers. This framework is applied within a wider initiative to assess the current available evidence on the clinical validity of biomarkers for AD, for the final aim to identify gaps and research priorities, and to inform coordinated research efforts boosting AD biomarkers research.

Original languageEnglish (US)
Pages (from-to)141-152
Number of pages12
JournalNeurobiology of Aging
Volume52
DOIs
StatePublished - Apr 1 2017

Fingerprint

Alzheimer Disease
Biomarkers
Research
Validation Studies
Health Services Needs and Demand
Population
Neoplasms

Keywords

  • Alzheimer
  • Biomarkers
  • Dementia
  • Early diagnosis
  • Methodology
  • Validation

ASJC Scopus subject areas

  • Neuroscience(all)
  • Aging
  • Developmental Biology
  • Geriatrics and Gerontology
  • Clinical Neurology

Cite this

The biomarker-based diagnosis of Alzheimer's disease. 2—lessons from oncology. / Geneva Task Force for the Roadmap of Alzheimer's Biomarkers.

In: Neurobiology of Aging, Vol. 52, 01.04.2017, p. 141-152.

Research output: Contribution to journalReview article

Geneva Task Force for the Roadmap of Alzheimer's Biomarkers. / The biomarker-based diagnosis of Alzheimer's disease. 2—lessons from oncology. In: Neurobiology of Aging. 2017 ; Vol. 52. pp. 141-152.
@article{e61d0086514a4b9481094cdc09d54416,
title = "The biomarker-based diagnosis of Alzheimer's disease. 2—lessons from oncology",
abstract = "Biomarkers for the diagnosis of Alzheimer's disease (AD) are not yet validated for use in clinical settings. We aim to provide a methodological framework for their systematic validation, by reference to that developed for oncology biomarkers. As for this discipline, the steps for the systematic validation of AD biomarkers need to target analytical validity, clinical validity, and clinical utility. However, the premises are different from oncology: the nature of disease (neurodegeneration vs. cancer), the purpose (improve diagnosis in clinically affected vs. screening preclinical individuals), and the target population (mild cognitive impairment patients referring to memory clinics vs. general population) lead to important differences, influencing both the design of validation studies and the use of selected biomarkers. This framework is applied within a wider initiative to assess the current available evidence on the clinical validity of biomarkers for AD, for the final aim to identify gaps and research priorities, and to inform coordinated research efforts boosting AD biomarkers research.",
keywords = "Alzheimer, Biomarkers, Dementia, Early diagnosis, Methodology, Validation",
author = "{Geneva Task Force for the Roadmap of Alzheimer's Biomarkers} and Marina Boccardi and Valentina Gallo and Yutaka Yasui and Paolo Vineis and Alessandro Padovani and Urs Mosimann and Panteleimon Giannakopoulos and Gabriel Gold and Bruno Dubois and Jack, {Clifford R Jr.} and Bengt Winblad and Frisoni, {Giovanni B.} and Emiliano Albanese",
year = "2017",
month = "4",
day = "1",
doi = "10.1016/j.neurobiolaging.2017.01.021",
language = "English (US)",
volume = "52",
pages = "141--152",
journal = "Neurobiology of Aging",
issn = "0197-4580",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - The biomarker-based diagnosis of Alzheimer's disease. 2—lessons from oncology

AU - Geneva Task Force for the Roadmap of Alzheimer's Biomarkers

AU - Boccardi, Marina

AU - Gallo, Valentina

AU - Yasui, Yutaka

AU - Vineis, Paolo

AU - Padovani, Alessandro

AU - Mosimann, Urs

AU - Giannakopoulos, Panteleimon

AU - Gold, Gabriel

AU - Dubois, Bruno

AU - Jack, Clifford R Jr.

AU - Winblad, Bengt

AU - Frisoni, Giovanni B.

AU - Albanese, Emiliano

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Biomarkers for the diagnosis of Alzheimer's disease (AD) are not yet validated for use in clinical settings. We aim to provide a methodological framework for their systematic validation, by reference to that developed for oncology biomarkers. As for this discipline, the steps for the systematic validation of AD biomarkers need to target analytical validity, clinical validity, and clinical utility. However, the premises are different from oncology: the nature of disease (neurodegeneration vs. cancer), the purpose (improve diagnosis in clinically affected vs. screening preclinical individuals), and the target population (mild cognitive impairment patients referring to memory clinics vs. general population) lead to important differences, influencing both the design of validation studies and the use of selected biomarkers. This framework is applied within a wider initiative to assess the current available evidence on the clinical validity of biomarkers for AD, for the final aim to identify gaps and research priorities, and to inform coordinated research efforts boosting AD biomarkers research.

AB - Biomarkers for the diagnosis of Alzheimer's disease (AD) are not yet validated for use in clinical settings. We aim to provide a methodological framework for their systematic validation, by reference to that developed for oncology biomarkers. As for this discipline, the steps for the systematic validation of AD biomarkers need to target analytical validity, clinical validity, and clinical utility. However, the premises are different from oncology: the nature of disease (neurodegeneration vs. cancer), the purpose (improve diagnosis in clinically affected vs. screening preclinical individuals), and the target population (mild cognitive impairment patients referring to memory clinics vs. general population) lead to important differences, influencing both the design of validation studies and the use of selected biomarkers. This framework is applied within a wider initiative to assess the current available evidence on the clinical validity of biomarkers for AD, for the final aim to identify gaps and research priorities, and to inform coordinated research efforts boosting AD biomarkers research.

KW - Alzheimer

KW - Biomarkers

KW - Dementia

KW - Early diagnosis

KW - Methodology

KW - Validation

UR - http://www.scopus.com/inward/record.url?scp=85015637626&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015637626&partnerID=8YFLogxK

U2 - 10.1016/j.neurobiolaging.2017.01.021

DO - 10.1016/j.neurobiolaging.2017.01.021

M3 - Review article

VL - 52

SP - 141

EP - 152

JO - Neurobiology of Aging

JF - Neurobiology of Aging

SN - 0197-4580

ER -